title: ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy.
abstract: BACKGROUND
  Anaplastic lymphoma kinase-positive (ALK+) anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma, which has strong expression of cluster of differentiation (CD)-30 and ALK. ALCL sometimes can involve the bone marrow, and in advanced stages, it can produce destructive bone lesions. But ALK+ ALCL with prominent bone involvement is very rare, especially in children.
  
  
  METHODS
  A 13-year-old boy presented with waist pain and low-grade fever for 8 months. The biopsy of soft tissue lesions around the thoracic spine showed that these cells were positive for ALK-1, CD30, leukocyte common antigen, CD3, CD4, and CD8, as well as being negative for epithelial membrane antigen and pan-cytokeratin, which revealed ALCL. After six cycles of a regimen consisting of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate and cytarabine (hyper-CVAD/MA) and autologous hematopoietic stem cell transplantation, he achieved complete remission (CR).
  
  
  CONCLUSIONS
  It is generally believed that the regimen consisting of cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, and prednisolone (CHOP) is also applicable to ALCL. Because of the tendency of rapid progression and the frequency of B symptoms, ALCL in children and young adults is treated with high-grade chemotherapy such as hyper-CVAD/MA.
authors.affiliation: Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
authors.forename: Chen
authors.initials: C
authors.lastname: Tian
authors.affiliation: Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
authors.forename: Hongliang
authors.initials: H
authors.lastname: Yang
authors.affiliation: Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
authors.forename: Yafei
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
authors.forename: Yizhuo
authors.initials: Y
authors.lastname: Zhang
keywords: anaplastic large cell lymphoma; anaplastic lymphoma kinase; bone involvement; hyper-CVAD/MA
references.citation: Adv Anat Pathol. 2015 Jan;22(1):29-49
references.pmid: 25461779
references.citation: PLoS One. 2015 Apr 13;10(4):e0121378
references.pmid: 25874976
references.citation: Pediatr Hematol Oncol. 2013 Sep;30(6):509-19
references.pmid: 23758281
references.citation: Blood. 2015 Jul 16;126(3):336-45
references.pmid: 25921060
references.citation: Br J Haematol. 2015 Aug;170(4):443
references.pmid: 26018037
references.citation: Br J Haematol. 2015 Feb;168(4):557-63
references.pmid: 25312752
references.citation: Blood. 1985 Oct;66(4):848-58
references.pmid: 3876124
references.citation: Pediatr Hematol Oncol. 2014 Sep;31(6):518-27
references.pmid: 25116372